Enterocolitis in Patients with Cancer Treated with Docetaxel
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Enterocolitis in Patients with Cancer Treated with Docetaxel |
| Type de publication | Journal Article |
| Year of Publication | 2018 |
| Auteurs | Fiteni F, Paillard M-J, Orillard E, Lefebvre L, Nadjafizadeh S, Selmani Z, Benhamida S, Roland A, Baumann A, Vienot A, Houede N, Pivot X |
| Journal | ANTICANCER RESEARCH |
| Volume | 38 |
| Pagination | 2443-2446 |
| Date Published | APR |
| Type of Article | Article |
| ISSN | 0250-7005 |
| Mots-clés | Cancer, Chemotherapy, Docetaxel, Enterocolitis, typhlitis |
| Résumé | {Background: Enterocolitis is a rare, but serious gastrointestinal complication associated with docetaxel-based chemotherapy in patients with cancer. The incidence, clinical presentation and outcome of enterocolitis in patients with cancer treated with docetaxel-based chemotherapy was assessed in this study Patients and Methods: All patients treated with docetaxel for cancer between January 2010 and December 2014 at the University Hospital of Besancon were identified and their medical records reviewed. Results: During this period, 1,227 patients received docetaxel chemotherapy and gastrointestinal events occurred in 381 (31.1%) patients. In multivariate analysis, a higher risk of gastrointestinal events was associated with a higher dose of docetaxel (>= 75 mg/m(2)) (odds ratio(OR)= 46.2; 95% confidence interval(CI)= 5.4-397.0 |
| DOI | 10.21873/anticanres.12497 |